Glenmark
A new way for a new world

March 15, 2013

The Manager
Listing Dept,
The National Stock Exchange of India Ltd
Plot No. C/1,G Block
Bandra Kurla Complex
Bandra (E) Mumbai-400051

Dear Sir,

We are enclosing herewith a press release informing **"Glenmark confirms patent challenge for its generic version of FINACEA"** for your information and record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.

Sanjay Chowdhary
Jt. Company Secretary &Compliance Officer

Tel: 4018 9999 / 4018 9879
Fax No: 4018 9986 (Legal & Secretarial Dept.)

Encl: As above

Glenmark Generics Ltd.

Glenmark
A new way for a new world

Press Release For Immediate Release

Glenmark confirms patent challenge for its generic version of FINACEA

March 15, 2013 : Glenmark Generics Limited confirms that it has filed an Abbreviated New Drug Application (ANDA) for Azelaic Acid, Gel 15% Topical, with the U.S. Food and Drug Administration (FDA) with a Paragraph IV Certification for the Orange-Book listed patent. Glenmark's ANDA product is a generic version of FINACEA, which is indicated for the topical treatment of inflammatory papules and pustules of mild to moderate rosacea.

Intendis GmbH, Intraserv GmbH & Co. KG, Bayer Healthcare Pharmaceuticals Inc. filed suit against Glenmark Generics Limited and Glenmark Generics Inc. on March 14, 2013, in the United States District Court for the District of Delaware, seeking to prevent Glenmark from commercializing its ANDA product prior to the expiration of U.S. Patent No. 6,534,070. This lawsuit was filed under the provisions of the Hatch-Waxman Act, which triggers a stay of final FDA approval of Glenmark's ANDA product for up to 30 months or until final resolution of the matter before the Court, whichever occurs sooner.

Based on available information, Glenmark believes it may be a "first applicant" to file an ANDA for the generic version of FINACEA and may be entitled to 180 days of generic market exclusivity.

According to the IMS health data for the twelve months ending September 30, 2012, FINACEA had total U.S. sales of approximately $ 95 million.

About Glenmark Generics Limited.

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America and developing an EU presence It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

#####

For further information, please contact:
Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India Tel: [+91 22] 40189919/984
Email : connect@glenmark-generics.com